Media ReleasesImugene Limited

View All Imugene Limited News

Imugene Announce CF33 Oncolytic Virus Clinical Trial Program Update

SYDNEY Australia 21 October 2019: Imugene Limited (ASX: IMU) is pleased to provide an update on the preliminary clinical development plan (CDP) for the proposed exclusive license of the patents covering the CF33 oncolytic virus technology, which is subject to shareholders’ approval at an Extraordinary Meeting of Shareholders to be held on 18th November 2019.

The CF33 oncolytic virus (OV) was developed in the lab of Professor Yuman Fong, an internationally recognised surgeon and scientist at City of Hope, a world-renowned independent research and treatment centre for cancer, diabetes and other life-threatening diseases based in California.

For further information please download the attached PDF:
Download this document